Abstract:Background: The ex vivo production of CD34+ hematopoietic progenitor cells from human bone-marrow mesenchymal stromal cells derived induced pluipotent stem cells (iPSCs) could serve as a feasible way to study patient-specific hematological disease from the perspective of hematopoietic differentiation. Different studies using virus-based or virus-free methods to reprogramming somatic cells into iPSCs by using fewer than four transcription factors, of which have the potential to differentiation in CD34+ hematopoietic progenitor cells. In this study, we demonstrate the generation of putative iPS cells from BMSCs with single OCT4 by plasmid transfection, which can differentiate into hematopoietic progenitor cells in defined culture system.Objective: To generate induced pluripotent stem cells (iPSCs) from bone marrow stromal cells (BMSCs) using a plasmid pcDNA3.1 constructed with a single transcription factor gene OCT4 (pcDNA3.1-OCT4) and to evaluate the hematopoietic differentiation potential of the putative BMSCs-iPSCs.Methods: BMSCs with ectopic high expression of OCT4 (BMSCs-OCT4) previously established by our group were cultured in traditional human ESC medium. Colonies with characteristic embryonic stem (ES) cell morphologies were selected and expanded in vitro. The undifferentiated status of putative BMSCs-iPSCs was confirmed by alkaline phosphatase (ALP) staining, telomerase activity assay, pluripotent marker expression and differentiation in vitro to form EBs and in vivo teratoma formation. The expression of pluripotent markers and ES markers were verified by RT-PCR, flow cytometry (FCM) and cellular immunofluorescence assay (CIFA). The hematopoietic differentiation potential into CD34+ progenitor cells by exposure to a defined culture system supplemented with a cocktail of hematopoietic growth factors was evaluated, of which the expression was confirmed by RT-PCR and FCM.Results: BMSCs were successfully reprogrammed into pluripotent stem cells resembling ESCs by introduction single transcription factor OCT4 gene constructed into the eukaryogenic plasmid pcDNA3.1. The putative BMSC-iPSCs were positive for ALP and telomerase activity, as well as the pluripotent stem cell markers including TRA-1-60, SSEA4, TRA-1-81, SOX2 and NANOG as detected by FCM and CIFA. Moreover, the above MSCs-OCT4 could form EBs ex vivo and express ectoderm (TUBB3+, WNT1+), mesoderm (Brachyury+, TBX20+), and endoderm (SPARC+) genes. By treatment with a cocktail containing BMP4 (50ng/ml), IL-3 (10ng/ml), IL-6 (10ng/ml), Flt-3 Ligand (300ng/ml), SCF (300ng/ml) and G-CSF (50ng/ml), the proportion of CD34+ progenitor cells increased from 0.93±0.46% in untransfected parental BMSCs and 1.58±1.29% in undifferentiated BMSC-iPS cells to 16.16±1.27% and 25.40±3.08% in day 14 and 21 differentiated BMSC-iPS cells, respectively. Moreover, the proportion of CD34+ progenitor cells were higher in the group with diverse concentration of growth factor cocktail induction, the proportion of CD34+ cells reached 31.39±3.60% and 73.68±6.63% in day 14 and 21 differentiated BMSC-iPS cells, respectively.Conclusion: In this study, we have clearly demonstrated the generation of putative iPS cells (or partly reprogrammed iPSCs from BMSCs with ectopic high expression of OCT4 by plasmid transfection). The BMSCs-derived iPSCs display the typical morphology and growth pattern as iPS cells when they are maintained in undifferentiated pluripotent state. Moreover, the putative BMSCs-derived iPSCs can differentiate into hematopoietic progenitor cells in defined culture system containing a cocktail of six or seven growth factors. Our findings provide a feasible way to generate hematopoietic progenitor cells using patient-specific iPSCs generated by plasmid transfection for hematological disease modeling.

Continuous human iPSC-macrophage mass production by suspension culture in stirred tank bioreactors

Standardized generation of human iPSC-derived hematopoietic organoids and macrophages utilizing a benchtop bioreactor platform under fully defined conditions

Differentiation of Human-Induced Pluripotent Stem Cells to Macrophages for Disease Modeling and Functional Genomics

Efficient and reproducible generation of human iPSC-derived cardiomyocytes and cardiac organoids in stirred suspension systems

Automated Production at Scale of Induced Pluripotent Stem Cell-Derived Mesenchymal Stromal Cells, Chondrocytes and Extracellular Vehicles: Towards Real-Time Release

Single OCT4 gene introduced into human bone-marrow derived mesenchymal stromal cells can generate putative iPS cells with the potential to differentiate into CD34+ hematopoietic progenitor cells ex vivo

Differentiation of monocytes and polarized M1/M2 macrophages from human induced pluripotent stem cells

Large-Scale Production of Human iPSC-Derived Macrophages for Drug Screening

Process Intensification in Human Pluripotent Stem Cell Expansion with Microcarriers

Efficient and reproducible generation of human iPSC-derived cardiomyocytes using a stirred bioreactor

Standardized qc assays and large scale expansion of pluripotent stem cells using an automated closed system.

Investigating the feasibility of scale up and automation of human induced pluripotent stem cells cultured in aggregates in feeder free conditions

A cost-effective and efficient reprogramming platform for large-scale production of integration-free human induced pluripotent stem cells in chemically defined culture

Scalable expansion of iPSC and their derivatives across multiple lineages

Optimized and Scalable Precoating-Free Reprogramming of Human Peripheral Blood Mononuclear Cells into iPSCs

Standardized production of hPSC-derived cardiomyocyte aggregates in stirred spinner flasks

Matrix-free human pluripotent stem cell manufacturing by seed train approach and intermediate cryopreservation

Controlling expansion and cardiomyogenic differentiation of human pluripotent stem cells in scalable suspension culture

Selecting Monoclonal Cell Lineages from Somatic Reprogramming Using Robotic-Based Spatial-Restricting Structured Flow

Using Microfluidics to Generate Human Naïve and Primed Pluripotent Stem Cells

Scalable manufacture of therapeutic mesenchymal stromal cell products on customizable microcarriers in vertical wheel bioreactors that improve direct visualization, product harvest, and cost